Chinanews.com, November 11 The National Health Commission held a press conference on November 15 to introduce the Healthy China Action - Cardiovascular and Cerebrovascular Disease Prevention and Control Action and Cancer Prevention and Control Action Implementation Plan (11-15). Daniel Zhang, Secretary of the Party Committee of the National Cancer Center, said at the meeting that our country attaches great importance to the research and development and promotion of cancer prevention and control technology, and the technical level and innovation ability have been continuously enhanced. The five-year survival rate of cancer patients in China has steadily improved over the years, and many advanced patients can survive with tumors for a long time, and the quality of life has also been greatly improved. For example, the five-year survival rate of breast cancer in China has reached 2023%, which has basically reached the level of diagnosis and treatment in developed countries in the world. The five-year survival rate of esophageal cancer in China is higher than that of European and American countries, and the incidence and mortality of esophageal cancer in some regions have shown a downward trend.
Daniel Zhang introduced that at present, some tumor prevention and treatment technologies in China have approached or reached the international advanced level, in the prevention of tumors, the domestic HPV bivalent vaccine has entered the population use, the National Cancer Center developed based on high-risk concentration technology to explore the most common 6 types of cancer joint screening program, for international cancer screening provides a new idea. In terms of clinical treatment, China's first new surgical technologies such as anatomical partial lobectomy, esophageal cancer without tube and continuation, and colorectal cancer NOSES have greatly improved the effect of surgical treatment. In terms of internal medicine, we have established a multi-omics model based on tissue and liquid biopsy to accurately diagnose and treat lung cancer and other cancers, and developed independent innovative drugs such as icotinib and eutidelone, breaking the market monopoly of similar foreign drugs. In terms of radiotherapy, China has successfully developed the software of automatic delineation of artificial intelligence radiotherapy, and the level of radiotherapy has been significantly improved.
Daniel Zhang stressed that we still have a lot of work to do in cancer prevention and control technology, with the continuous development of China's economy and society, especially the continuous reform and improvement of the scientific research system, China's cancer prevention and control technology will further accelerate its development, gradually narrow the gap with developed countries, and reach the international advanced level. The National Cancer Center will continue to play a leading role in technology, promote the construction of collaborative innovation networks, strengthen the innovation of major sources of cancer prevention and control and the innovation of disruptive technologies, and continue to meet the health needs of the Chinese people.